Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Videos|April 8, 2014
Diagnosing Prostate Cancer: The Bioptic Gun, PET/CT Scans, and Mapping Biopsies
Author(s)E. David Crawford, MD
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer.
Advertisement
Clinical Pearls
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer. Crawford presented at the7th Annual Interdisciplinary Prostate Cancer Congress™on defining candidates for active surveillance and modifying biopsy techniques.
- The development of the bioptic gun has revolutionized the diagnosis of prostate cancer but has also created controversy.
- PET and CT scans are a waste in localized prostate cancer; physicians are not worried about the disease spreading.
- Low-risk patients are now being defined better with transperineal 3D mapping biopsies, which are done under the scrotum at 5 mm intervals.
- Once 3D reconstruction of the prostate is completed, a physician can decide whether to treat with laser ablation, freezing, or definitive therapy.
Advertisement
Related to this article
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5